首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients
【24h】

Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients

机译:利妥昔单抗可解除类风湿关节炎患者疾病活动与关节损伤之间的紧密联系

获取原文
获取原文并翻译 | 示例
       

摘要

Background/objective: Progression of joint damage is linked to disease activity. This link is dissociated upon treatment with tumour necrosis factor (TNF)- or IL-6-inhibitors plus methotrexate (MTX). It is hitherto unknown if this may also be true for therapies targeting B-cells. We thus evaluated if rituximab (RTX) therapy inhibits joint damage irrespective of its effects on disease activity. Methods: We used a random 90% sample of data from two arms of the IMAGE trial comprising patients with active early rheumatoid arthritis (RA) receiving MTX (n=188) or MTX+RTX 1000 mg (n=204). Patients were divided into low, moderate and high disease activity at one year of treatment by simplified disease activity index (low disease activity (LDA), moderate disease activity (MDA), high disease activity (HDA)), or by swollen joint count (SJC) or C reactive protein (CRP) tertiles. Progression of damage by the Genant modified total Sharp score (TGSS) was compared between therapies (Kruskal-Wallis, Wilcoxon tests) for each of these subgroups. Results: In patients treated with MTX, 1-year progression of TGSS In LDA, MDA and HDA was 0.40±0.88, 1.04±1.73, and 1.31±3.02, respectively. In contrast, on RTX+MTX, TGSS progression was 0.38±1.07, 0.39±1.28, and -0.05±0.44, respectively (for MDA and HDA the progression of TGSS was signi ficantly lower in the combined group than in the MTX group: p=0.003 and p=0.05, respectively). Additional analyses (tertiles of SJC, CRP, and matching for disease activity) confirmed the primary analysis. Conclusions: In early RA, progression of joint damage increases with increasing disease activity on MTX. RTX plus MTX retards damage independently of its effects on disease activity, since even in HDA destruction is halted, contrasting MTX monotherapy. This indicates that beyond cytokine blockade (TNF- and IL-6 inhibitors), also celldirected therapy (anti-CD20 antibody) conveys profound anti-destructive effects and dissociates the link between disease activity and joint damage.
机译:背景/目的:关节损伤的进展与疾病活动有关。用肿瘤坏死因子(TNF)或IL-6抑制剂加甲氨蝶呤(MTX)治疗后,此联系解离。迄今为止,对于靶向B细胞的疗法是否也如此还不为人知。因此,我们评估了利妥昔单抗(RTX)治疗是否抑制关节损伤,无论其对疾病活动的影响如何。方法:我们从IMAGE试验的两组中随机抽取90%的数据样本,包括接受MTX(n = 188)或MTX + RTX 1000 mg(n = 204)的活动性早期类风湿关节炎(RA)患者。根据简化的疾病活动指数(低疾病活动度(LDA),中度疾病活动度(MDA),高疾病活动度(HDA))或关节肿胀,将患者在治疗1年时分为低,中和高疾病活动度( SJC)或C反应蛋白(CRP)三分位数。比较这些亚组在治疗方法(Kruskal-Wallis,Wilcoxon试验)之间Genent改良总夏普评分(TGSS)对损伤的进展。结果:在接受MTX治疗的患者中,TGSS在LDA,MDA和HDA中的1年进展分别为0.40±0.88、1.04±1.73和1.31±3.02。相比之下,在RTX + MTX上,TGSS的进展分别为0.38±1.07、0.39±1.28和-0.05±0.44(对于MDA和HDA,联合组的TGSS的进展显着低于MTX组:p分别为0.003和p = 0.05)。其他分析(SJC,CRP的三分位数以及疾病活动的匹配度)证实了主要分析。结论:在早期RA中,关节损伤的进展随着对MTX的疾病活动的增加而增加。 RTX加MTX可以独立于其对疾病活动的影响而延缓伤害,因为即使在HDA中,破坏也可以停止,这与MTX单一疗法相反。这表明,除了细胞因子阻滞剂(TNF-和IL-6抑制剂)以外,细胞定向疗法(抗CD20抗体)还具有深远的抗破坏作用,并消除了疾病活动性与关节损伤之间的联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号